Table 1.
Baseline characteristics of 1,098 patients with Escherichia coli BSI stratified by ESBL production
| Parameter/category | ESBL-positive (n=115) | ESBL-negative (n=983) | P-value |
|---|---|---|---|
| Hospital-acquired BSI* | 67 (58%) | 382 (39%) | <0.001 |
| Age, years | 59 (44–71) | 67 (54–75) | <0.001 |
| Male* | 74 (64%) | 521 (53%) | 0.018 |
| In-house mortality* | 30 (26%) | 181 (18%) | 0.076 |
| Length of hospital stay, total days | 27 (12–53) | 15 (8–32) | <0.001 |
| Length of stay before BSI onset, days | 7 (0–20) | 1 (0–10) | <0.001 |
| Charlson comorbidity index | 5 (3–8) | 5 (3–8) | 0.227 |
| Myocardial infarct* | 5 (4%) | 28 (3%) | 0.381 |
| Congestive heart failure* | 19 (17%) | 148 (15%) | 0.681 |
| Peripheral vascular disease* | 19 (17%) | 83 (8%) | 0.007 |
| Cerebrovascular disease* | 8 (7%) | 56 (6%) | 0.673 |
| Dementia* | 2 (2%) | 21 (2%) | 1.000 |
| Chronic lung disease* | 11 (10%) | 109 (11%) | 0.643 |
| Rheumatic disease* | 0 | 32 (3%) | 0.050 |
| Peptic ulcer* | 6 (6%) | 36 (4%) | 0.436 |
| Mild liver disease* | 12 (10%) | 121 (12%) | 0.652 |
| Diabetes without complication* | 14 (12%) | 192 (20%) | 0.058 |
| Diabetes with complication* | 8 (7%) | 62 (6%) | 0.839 |
| Renal disease* | 55 (48%) | 425 (43%) | 0.372 |
| Malign tumor* | 25 (22%) | 237 (24%) | 0.644 |
| Liver disease* | 9 (8%) | 70 (7%) | 0.848 |
| Metastasis* | 14 (12%) | 139 (14%) | 0.577 |
| HIV* | 2 (2%) | 9 (1%) | 0.617 |
| Hemiplegia* | 5 (4%) | 37 (4%) | 0.795 |
| Leukemia* | 15 (13%) | 85 (9%) | 0.124 |
| Lymphoma* | 5 (4%) | 66 (7%) | 0.424 |
Notes:
*
Categorical variables were tested using Fisher’s exact test, and are presented as number (percentage). Continuous variables were tested using the Wilcoxon rank-sum test, and are presented as medians (interquartile range).
Abbreviations: BSI, bloodstream infection; ESBL, extended-spectrum β-lactamase; HIV, human immunodeficiency virus.